FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2276408020> ?p ?o ?g. }

• W2276408020 endingPage "609" @default.
• W2276408020 startingPage "601" @default.
• W2276408020 abstract "Abstract Although the cause(s) of clinical drug resistance in non-Hodgkin's lymphomas (NHL) is unknown, in vitro studies suggest that abnormalities of the p53 gene, bcl-2 overexpression, and low tumor proliferation rates may increase chemotherapy resistance. We analyzed tumor tissue from 75 patients with relapsed/refractory NHL (Working Formulation A through H) for p53 mutation/overexpression (abnormality), bcl-2 expression, and tumor proliferation and correlated them with multiple clinical characteristics, response to therapy, disease-free survival, and overall survival (OS). All tumor biopsy specimens were obtained within 6 weeks of treatment with EPOCH (infusional etoposide, vincristine, and doxorubicin and bolus prednisone and cyclophosphamide) chemotherapy. Overall, 16 (21%) tumors had a p53 abnormality. Of 13 tumors with overexpression, mutations were confirmed by sequence analysis in 11, and, in 44 tumors without overexpression, 3 showed mutations. A multivariate analysis showed that tumors with a p53 abnormality were more likely to be drug resistant than tumors with normal p53 (56% v 17%; P2 = .008) and to have a shorter median progression-free survival (PFS; 2.1 v 8.2 months; P2 = .008) and OS (11.7 v 21.5 months; P2 = .038), respectively. The presence of a p53 abnormality did not correlate with any clinical characteristic, bcl-2 expression, or tumor proliferation. A significant correlation was found between low tumor proliferation and drug resistance in a univariate (P2 &lt; .006) but not multivariate analysis. Patients with tumor proliferation of less than 80% were significantly more likely to have no response to therapy (31% v 6%) or to fail to achieve a complete response (16% v 44%) and tended to have shorter PFS and OS than did patients with higher proliferation. No significant association was found between bcl-2 expression and drug resistance, PFS or OS, although patients with intermediate-grade histologies and high bcl-2 expression tended to be drug resistant as compared with low level expressors (P2 &lt; .065). Of interest was the finding of a significant association between high bcl-2 and low tumor proliferation (P2 = .0045). In studies that have found an association between high bcl-2 expression and short PFS, bcl-2 may have been a surrogate for low tumor proliferation. Further studies are warranted to examine this question. These results suggest that p53 mutation and low tumor proliferation, but not bcl-2, may be important causes of clinical drug resistance in NHL." @default.
• W2276408020 created "2016-06-24" @default.
• W2276408020 creator A5024701461 @default.
• W2276408020 creator A5044239219 @default.
• W2276408020 creator A5049385918 @default.
• W2276408020 creator A5067324677 @default.
• W2276408020 creator A5071873190 @default.
• W2276408020 creator A5081471690 @default.
• W2276408020 creator A5089779163 @default.
• W2276408020 date "1997-01-15" @default.
• W2276408020 modified "2023-10-13" @default.
• W2276408020 title "Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas" @default.
• W2276408020 cites W1486772440 @default.
• W2276408020 cites W1565408903 @default.
• W2276408020 cites W1853245606 @default.
• W2276408020 cites W1862918409 @default.
• W2276408020 cites W1892527323 @default.
• W2276408020 cites W1952207705 @default.
• W2276408020 cites W2005934064 @default.
• W2276408020 cites W2009183764 @default.
• W2276408020 cites W2068909560 @default.
• W2276408020 cites W2075696892 @default.
• W2276408020 cites W2079811957 @default.
• W2276408020 cites W2081894694 @default.
• W2276408020 cites W2098142356 @default.
• W2276408020 cites W2125686177 @default.
• W2276408020 cites W2134979684 @default.
• W2276408020 cites W2138776665 @default.
• W2276408020 cites W2168769461 @default.
• W2276408020 cites W2239810334 @default.
• W2276408020 cites W2253853328 @default.
• W2276408020 cites W2274928514 @default.
• W2276408020 cites W2408033184 @default.
• W2276408020 cites W3112177578 @default.
• W2276408020 cites W4205736005 @default.
• W2276408020 cites W4243182105 @default.
• W2276408020 cites W4252168887 @default.
• W2276408020 cites W4254970489 @default.
• W2276408020 cites W4293241248 @default.
• W2276408020 doi "https://doi.org/10.1182/blood.v89.2.601" @default.
• W2276408020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9002964" @default.
• W2276408020 hasPublicationYear "1997" @default.
• W2276408020 type Work @default.
• W2276408020 sameAs 2276408020 @default.
• W2276408020 citedByCount "218" @default.
• W2276408020 countsByYear W22764080202012 @default.
• W2276408020 countsByYear W22764080202013 @default.
• W2276408020 countsByYear W22764080202014 @default.
• W2276408020 countsByYear W22764080202015 @default.
• W2276408020 countsByYear W22764080202016 @default.
• W2276408020 countsByYear W22764080202017 @default.
• W2276408020 countsByYear W22764080202018 @default.
• W2276408020 countsByYear W22764080202019 @default.
• W2276408020 countsByYear W22764080202020 @default.
• W2276408020 countsByYear W22764080202021 @default.
• W2276408020 countsByYear W22764080202023 @default.
• W2276408020 crossrefType "journal-article" @default.
• W2276408020 hasAuthorship W2276408020A5024701461 @default.
• W2276408020 hasAuthorship W2276408020A5044239219 @default.
• W2276408020 hasAuthorship W2276408020A5049385918 @default.
• W2276408020 hasAuthorship W2276408020A5067324677 @default.
• W2276408020 hasAuthorship W2276408020A5071873190 @default.
• W2276408020 hasAuthorship W2276408020A5081471690 @default.
• W2276408020 hasAuthorship W2276408020A5089779163 @default.
• W2276408020 hasBestOaLocation W22764080201 @default.
• W2276408020 hasConcept C114851261 @default.
• W2276408020 hasConcept C126322002 @default.
• W2276408020 hasConcept C142724271 @default.
• W2276408020 hasConcept C143998085 @default.
• W2276408020 hasConcept C144301174 @default.
• W2276408020 hasConcept C2776694085 @default.
• W2276408020 hasConcept C2776755627 @default.
• W2276408020 hasConcept C2778119113 @default.
• W2276408020 hasConcept C2779338263 @default.
• W2276408020 hasConcept C2779429289 @default.
• W2276408020 hasConcept C38180746 @default.
• W2276408020 hasConcept C502942594 @default.
• W2276408020 hasConcept C71924100 @default.
• W2276408020 hasConcept C86803240 @default.
• W2276408020 hasConcept C89423630 @default.
• W2276408020 hasConceptScore W2276408020C114851261 @default.
• W2276408020 hasConceptScore W2276408020C126322002 @default.
• W2276408020 hasConceptScore W2276408020C142724271 @default.
• W2276408020 hasConceptScore W2276408020C143998085 @default.
• W2276408020 hasConceptScore W2276408020C144301174 @default.
• W2276408020 hasConceptScore W2276408020C2776694085 @default.
• W2276408020 hasConceptScore W2276408020C2776755627 @default.
• W2276408020 hasConceptScore W2276408020C2778119113 @default.
• W2276408020 hasConceptScore W2276408020C2779338263 @default.
• W2276408020 hasConceptScore W2276408020C2779429289 @default.
• W2276408020 hasConceptScore W2276408020C38180746 @default.
• W2276408020 hasConceptScore W2276408020C502942594 @default.
• W2276408020 hasConceptScore W2276408020C71924100 @default.
• W2276408020 hasConceptScore W2276408020C86803240 @default.
• W2276408020 hasConceptScore W2276408020C89423630 @default.
• W2276408020 hasIssue "2" @default.
• W2276408020 hasLocation W22764080201 @default.
• W2276408020 hasOpenAccess W2276408020 @default.

• next